| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bc2b03342511abc88f60c63f2acd96d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_67950272fcf1c4252717a7ea3eadcafe |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08L77-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2430-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08K5-09 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P41-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-18 |
| filingDate |
2020-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea781790014c4e67f36feb66162050bb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcec229fb0dd7ff37a0e6985a02bb2ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5dda3fa3b1ea5257cb40925786cd1e5b |
| publicationDate |
2020-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020246127-A1 |
| titleOfInvention |
Biologically modified vascular grafts for improved bypass surgery outcomes |
| abstract |
The present disclosure provides a method for creating a Biologically Modified Vein Graft with improved survival by pretreating the vein to be used as a vascular graft with compositions comprising oligo-L-arginine, or salts thereof, and an organic acid or a salt thereof. The disclosure further provides methods of improving vascular vein graft survival comprising pretreating the graft for a set period of time with a set concentration of oligo-L-arginines in a buffer comprising either the organic acid or the salt thereof and flushing the BMVG before implantation with the same buffer absent the arginine oligomer. This treatment may prevent vein graft disease in the transplanted vessel. |
| priorityDate |
2019-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |